 | • レポートコード：MRC2203A417 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本市場調査レポートでは、世界のD-ダイマー市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、検査方法別（ポイントオブケア検査、実験室検査）分析、用途別（深部静脈血栓症（DVT）、肺塞栓症（PE）、静脈血栓塞栓症（VTE）、その他）分析、流通チャネル別（診断研究所、病院、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のD-ダイマー市場規模：検査方法別（ポイントオブケア検査、実験室検査） ・世界のD-ダイマー市場規模：用途別（深部静脈血栓症（DVT）、肺塞栓症（PE）、静脈血栓塞栓症（VTE）、その他） ・世界のD-ダイマー市場規模：流通チャネル別（診断研究所、病院、その他） ・世界のD-ダイマー市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Abbott Laboratories、Bio-Rad Laboratories Inc、Danaher Corporation、…） ・市場機会・将来傾向 |
The D-Dimer Market is anticipated to witness a healthy CAGR over the forecast period. The major factors driving the growth of the market are the rising global prevalence of pathological conditions like multiple cardiovascular indications, acute coronary syndromes, arterial or venous thromboembolism, and atrial fibrillation and non-pathological conditions such as rise in the geriatric population where the levels of D-dimer increase in the blood plasma. For instance, according to the Global Health And Wellness Report published in 2018, about 40% of the adults in United States have been diagnosed with some or other cardiovascular condition related to blood disorders which directly resulted in higher demand for efficient treatments and advanced coagulation testing techniques fueling the growth of the market throughout the forecasted period.
Key Market Trends
The Pulmonary Embolism Segment is Expected to Witness a Robust Growth Over the Forecast Period
- Growth of the pulmonary embolism segment is attributed to the growing global prevalence of this disease due to rise in blood plasma d-dimer levels among women and the rising geriatric population coupled with a higher burden of associated diseases. On the other hand, Deep Venous Thrombosis (DVT) testing is also likely to witness the highest growth rate over the forecast period due to the rise in a number of new cases across the world. For instance, according to the National Health Service (NHS) fact sheet (2019), every year, DVT affects one in every 1,000 individuals in the United Kingdom coupled with obese population and people over the age of 40. This factor is fueling the segment and contributing to the growth of global market revenue.
- Based on the end-users, the hospital segment is expected to dominate the d-dimer market. The dominance is due to a rise in the number of patients admitted to the hospitals for the early diagnosis of cardiovascular diseases and blood disorders as prescribed by physicians. On the other hand, the diagnostic laboratories are likely to witness the highest growth due to adoption of advanced technologies and availability of novel systems like Cobas h 232 POC system in the developed countries which can be used in different settings like ambulances, and emergency rooms driving the global d-dimer market over the forecast period.
North America Dominates the Market and Expected to do Same in the Forecast Period.
North America is expected to dominate the overall D-Dimer market throughout the forecast period. The dominance is due to the rising prevalence of cardiopulmonary disorders and blood disorders such as venous thromboembolism, strokes, disseminated intravascular coagulation among the huge population of elder individuals which generates higher demand for the D-Dimer test market. For instance, according to the report published by the Centers for Disease Control and Prevention (CDC) in March 2019, the risk of Deep vein thrombosis (DVT) increases with rise in obesity and age over 50. It has been estimated by CDC that about 900,000 people in the United States could be affected every year with DVT which directly drives for growth of the D-dimer testing market in the region. Also, a rise in the approvals from regulatory authorities along with ongoing clinical trial studies and increasing adoption of technology by the key players in the United States are likely to contribute the largest share of revenue in the region propelling the global D-Dimer market.
Competitive Landscape
The D-Dimer market is moderately competitive and consists of several major players. Few of the key players are entering into partnerships to develop novel methods and test kits while others are increasing their salesforce through partnering with the distributors to increase their market position globally. For instance, In October 2017, Abbott acquired Alere Inc, a global manufacturer of rapid point-of-care diagnostics and emerged as one of the leading point of care testing portfolio achieving leadership positions in key business segments across the geographies which is expected to impel the global D-Dimer market growth throughout the forecast period. Some of the companies which are currently dominating the market are F. Hoffmann-La Roche Ltd, Abbott Laboratories, Siemens AG, Bio-Rad Laboratories Inc, and Thermo Fisher Scientific.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Geriatric Population Along with Rise in Disposable Income
4.2.2 Rise in Global Prevalence of Cardiopulmonary Disorders such as Stroke and Pulmonary Embolism
4.3 Market Restraints
4.3.1 Stringent Regulation
4.3.2 Limitations Associated with the Tests
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Testing Method
5.1.1 Point of Care Testing
5.1.2 Laboratory Testing
5.2 By Application
5.2.1 Deep Vein Thrombosis (DVT)
5.2.2 Pulmonary Embolism (PE)
5.2.3 Venous Thromboembolism (VTE)
5.2.4 Others
5.3 By Distribution Channel
5.3.1 Diagnostic Laboratories
5.3.2 Hospitals
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United states
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Bio-Rad Laboratories Inc
6.1.3 Danaher Corporation
6.1.4 Beckton Dickinson
6.1.5 BioMerieux
6.1.6 F Hoffmann-La Roche AG
6.1.7 Siemens AG
6.1.8 Sysmex Corporation
6.1.9 Merck KGaA
6.1.10 Thermo Fisher Scientific
7 MARKET OPPORTUNITIES AND FUTURE TRENDS